Due to the infamy of Theranos, even those not involved in the world of healthcare, know something about blood diagnostics and the effort to make it less burdensome.
While the Theranos saga has burned investors, revealed a troubled entrepreneur and perhaps even created some hurdles for women entrepreneurs, other startups with similar aims haven’t given up their ambition to transform the world of complete blood count testing and other blood diagnostics. One of those is Israeli startup Sight Diagnostics. The company has raised more than $120 million and has received FDA approval to allow its Olo device to be used in moderately complex healthcare settings.
Changes in Nurse Staffing Answer Clinician Demands
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
In this episode, Daniel Levner, co-founder and chairman of the company’s scientific advisory board discusses the product and how computer vision and AI can change the world of blood diagnostics.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.